Search - tctmd.com

Displaying 761 - 780 of 1574

Sort: Relevancy | Date

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Mitchell W. Krucoff

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

News Conference News TCT 2018

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

Yael L. Maxwell

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Presenter: Anibal A. Damonte, Diego D Grinfeld, Alfredo E. Rodriguez, John A. Ambrose

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

News Conference News TCT 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

Todd Neale

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

Presentation TCT 2018

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Presenter: Valentin Fuster, Shao-Liang Chen

September 23, 2018

Presentation TCT 2018

Clinical Trial Considerations for Transcatheter TR Therapies

Presenter: Ori Ben-Yehuda

September 23, 2018

News Conference News TCT 2018

COAPT: MitraClip Reduces Repeat Hospitalizations, Mortality in Functional MR Patients With Severe HF

Shelley Wood

September 23, 2018

Presentation TCT 2018

Trialign Pioneering Work Technology and Clinical Updates

Presenter: Christopher U. Meduri

September 23, 2018

News Conference News TCT 2018

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Michael O'Riordan

September 22, 2018

Advertisement

How to Make Trials Larger, Simpler and Less Expensive

LEADERS FREE II: Summary and Clinical Implications

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Patient Perspectives on Sham-Controlled Trials

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

High Mortality but Durable Results With Valve-in-Valve TAVR

FDA Perspectives on Sham-Controlled Trials

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Clinical Trial Considerations for Transcatheter TR Therapies

COAPT: MitraClip Reduces Repeat Hospitalizations, Mortality in Functional MR Patients With Severe HF

Trialign Pioneering Work Technology and Clinical Updates

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content